Travers, Jared http://orcid.org/0000-0003-4786-604X
Rochman, Mark http://orcid.org/0000-0002-0818-927X
Miracle, Cora E.
Habel, Jeff E. http://orcid.org/0000-0001-5419-5913
Brusilovsky, Michael
Caldwell, Julie M. http://orcid.org/0000-0002-3855-299X
Rymer, Jeffrey K.
Rothenberg, Marc E. http://orcid.org/0000-0001-9790-6332
Funding for this research was provided by:
Campaign Urging Research for Eosinophilic Disease (CURED), Buckeye Foundation, Sunshine Charitable Foundation
Article History
Received: 24 August 2017
Accepted: 24 June 2018
First Online: 14 August 2018
Change Date: 5 September 2018
Change Type: Update
Change Details: This Article was originally published without the accompanying Peer Review File. This file is now available in the HTML version of the Article; the PDF was correct from the time of publication.
Competing interests
: M.E.R. is a consultant for Pulm One, Spoon Guru, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron and Novartis; has an equity interest in Pulm One, Spoon Guru, and Immune Pharmaceuticals; and has royalties from reslizumab (Teva Pharmaceuticals). M.E.R. is an inventor of several patents owned by Cincinnati Children’s. The remaining authors declare no competing interests.